AR132340A1 - Compuestos tricíclicos para el tratamiento de cáncer - Google Patents

Compuestos tricíclicos para el tratamiento de cáncer

Info

Publication number
AR132340A1
AR132340A1 ARP240100854A ARP240100854A AR132340A1 AR 132340 A1 AR132340 A1 AR 132340A1 AR P240100854 A ARP240100854 A AR P240100854A AR P240100854 A ARP240100854 A AR P240100854A AR 132340 A1 AR132340 A1 AR 132340A1
Authority
AR
Argentina
Prior art keywords
cancer treatment
tricyclic compounds
compounds
tricyclic
formula
Prior art date
Application number
ARP240100854A
Other languages
English (en)
Inventor
Jianguo Chen
Haixia Liu
Hong Shen
Junwei Xi
Weixing Zhang
Dan Zhao
Wei Zhu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR132340A1 publication Critical patent/AR132340A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (1), en donde R¹ a R⁴, A¹, A², M y L son como se describe en la presente, y su sal farmacéuticamente aceptable de estos, y composiciones que incluyen los compuestos y métodos para usar los compuestos.
ARP240100854A 2023-04-06 2024-04-05 Compuestos tricíclicos para el tratamiento de cáncer AR132340A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2023086590 2023-04-06

Publications (1)

Publication Number Publication Date
AR132340A1 true AR132340A1 (es) 2025-06-18

Family

ID=90721049

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100854A AR132340A1 (es) 2023-04-06 2024-04-05 Compuestos tricíclicos para el tratamiento de cáncer

Country Status (6)

Country Link
EP (1) EP4688791A1 (es)
JP (1) JP2026515652A (es)
CN (1) CN120917030A (es)
AR (1) AR132340A1 (es)
TW (1) TW202446387A (es)
WO (1) WO2024208934A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4596552A1 (en) 2022-09-29 2025-08-06 Guangzhou Joyo Pharmatech Co., Ltd Macrocyclic derivative and use thereof
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025201453A1 (en) * 2024-03-28 2025-10-02 Beigene (Suzhou) Co., Ltd. Macrocyclic compounds as ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026022119A1 (en) * 2024-07-24 2026-01-29 F. Hoffmann-La Roche Ag Ras inhibitors in combination therapy for use in treating cancers
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026082180A1 (zh) * 2024-10-18 2026-04-23 合肥盛浦医药科技有限公司 一种大环化合物、其中间体、其制备方法及其应用
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
CN119874607B (zh) * 2025-01-16 2025-11-21 南京艾康生物科技有限公司 一种1-boc-2,2-二甲基哌啶-4-酮的制备方法
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021091956A1 (en) * 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
EP4208261A1 (en) * 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CN117979966A (zh) * 2021-04-09 2024-05-03 锐新医药公司 使用sos1抑制剂和ras抑制剂治疗癌症
PE20240088A1 (es) * 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
WO2022251292A1 (en) * 2021-05-25 2022-12-01 Revolution Medicines, Inc. Methods for inhibiting ras

Also Published As

Publication number Publication date
TW202446387A (zh) 2024-12-01
CN120917030A (zh) 2025-11-07
JP2026515652A (ja) 2026-05-19
EP4688791A1 (en) 2026-02-11
WO2024208934A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
CO2025001184A2 (es) Compuestos macrocíclicos para el tratamiento de cáncer
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
CO2024017733A2 (es) Inhibidores macrocíclicos de kras para el tratamiento de cáncer
CO2025010435A2 (es) Compuestos tricíclicos para el tratamiento de cáncer
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
CL2022001392A1 (es) Compuestos tricíclicos sustituidos
AR133266A1 (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
PE20241299A1 (es) Derivados de exatecan y sus conjugados anticuerpo-farmaco
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
PE20220140A1 (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos
PE20251323A1 (es) Compuestos triciclicos y sus usos
MX394700B (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
PE20181045A1 (es) Compuestos utiles como inmunomoduladores
UY39574A (es) Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene
DOP2013000276A (es) Nuevos derivados de imidazol útiles para el tratamiento de artritis
CL2023002966A1 (es) Compuestos de oxoisoindolina sustituidos con piridinilo
ECSP11010804A (es) Compuestos orgánicos
DOP2024000102A (es) Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa
CL2024002479A1 (es) Compuestos derivados de diciclopropilo, moduladores de il-17a, y usos de estos.
AR130984A1 (es) Compuestos novedosos
AR131006A1 (es) Compuestos novedosos
BR112022019888A2 (pt) Compostos tricíclicos como inibidores de egfr
PE20240776A1 (es) Compuestos terapeuticos y procedimientos
MX2025002817A (es) Compuestos para el tratamiento del cancer
AR133167A1 (es) Macrociclos para el tratamiento de enfermedad autoinmunitaria